The podcast episodes discuss the potential impact of 23andMe's genetic data on healthcare and medical research, particularly in the realm of drug discovery.

For example, the "Extra: Why Is 23andMe Going Under? (Update)" episode features an interview with the CEO of 23andMe, exploring how the company's genetic data could drive medical research and drug development.

Additionally, the "A Good ACT To Follow" episode examines how the advocacy group ACT UP transformed healthcare policies and medical research for AIDS patients through their direct action tactics.